Beam Therapeutics Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

BEAM$27.02+2.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	September 30,2025	December 31,2024
Assets
Current assets:
Cash and cash equivalents	$267,960	$281,967
Marketable securities	807,010	568,773
Prepaid expenses and other current assets	23,577	27,409
Total current assets	1,098,547	878,149
Property and equipment, net	108,290	111,412
Restricted cash	6,656	8,144
Operating lease right-of-use assets	96,995	104,865
Other assets	593	1,254
Total assets	$1,311,081	$1,103,824
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$9,545	$3,871
Accrued expenses and other current liabilities	42,314	47,468
Current portion of derivative liabilities	6,500	8,400
Current portion of deferred revenue	110,320	108,858
Current portion of lease liability	12,688	13,469
Current portion of consideration liabilities	1,192	—
Total current liabilities	182,559	182,066
Long-term lease liability	138,732	147,956
Long-term portion of contingent consideration liabilities	6,708	1,131
Long-term portion of deferred revenue	10,160	33,218
Long-term portion of derivative liabilities	6,654	5,404
Other liabilities	266	504
Total liabilities	345,079	370,279
Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements)
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at September 30, 2025 and December 31, 2024, respectively	—	—
Common stock, $0.01 par value; 250,000,000 shares authorized, 101,359,765 and 83,633,069 issued and outstanding at September 30, 2025 and December 31, 2024, respectively	1,014	836
Additional paid-in capital	2,855,118	2,298,661
Accumulated other comprehensive (loss) income	790	679
Accumulated deficit	(1,890,920)	(1,566,631)
Total stockholders’ equity	966,002	733,545
Total liabilities and stockholders’ equity	$1,311,081	$1,103,824

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.